In the past 12 months, Velocity has randomized 25,000 patients into phase II and III studies in the US. The tech investments will enable Velocity to be more efficient in managing studies, identifying patients for studies, and increasing the frequency of participation in studies
Velocity Clinical Research Announces Three Key Tec | 16/02/2022 | By Darshana | 299
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy